Prasco Laboratories has entered into a marketing and distribution agreement with GlaxoSmithKline for generic Flonase Nasal Spray. Prasco, as GSK’s agent and on GSK’s behalf, will market and distribute Fluticasone Propionate Nasal Spray to all trade classes in the U.S. under a GSK/Prasco label.

“We are especially proud to have established this relationship with GSK, a global leader in the research-based pharmaceutical industry,” said Prasco chief executive officer E. Thomas Arington. “We look forward to working with GSK to provide more choices for patients in the generics market.”

“GlaxoSmithKline is always looking for opportunities to increase access to our medicines for patients,” said Stan Hull, GlaxoSmithKline senior vice president, U.S. Pharmaceuticals. “The arrangement with Prasco, a known leader in the generics market, allows GSK to expand participation in the generic market in a new way.”